ASXL1 and acute myeloid leukemia: In the present study, we developed an RUNX1, TP53, and ASXL1 mutation derived IPM based on TCGA AML cohort, and demonstrated that the IPM-defined risk independently predicted OS in AML, which was validated by GSE databases.